Aspen is proud to announce the addition of Tribuss to their extensive Antiretroviral Portfolio.
Tribuss is a fixed dose triple combination tablet of two nucleoside reverse transcriptase inhibitors (NRTI’s) and one non-nucleoside reverse transcriptase inhibitor (NNRTI).
Tribuss tablets contain tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg and efavirenz 600 mg.
The dosage of Tribuss is one tablet daily taken orally on a empty stomach. It is recommended that Tribuss be taken at bedtime in order to improve tolerability to efavirenz with respect to undesirable effects on the nervous system.
Tribuss is available in the following presentation:
Tribuss Tablets packed in 30’s, SEP excl. R 381.93, SEP incl. R 435.40 and Nappi Code 716630001.
Further information and trade enquiries may be directed to Bevan Fry on (011) 239 3423 or the Medical Information Hotline on 0800 118 088.
Tribuss is indicated for HIV infected adults and adolescents over 18 years of age for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infections.